

## Expression and Characterization of Purinergic Receptor, P2Y<sub>10</sub> in Hematopoietic Stem Cells

Lee, Eun-Jong and Dong-Ku Kim<sup>†</sup>

*Cell and Gene Therapy Research Institute, Graduate School of Life Science and Biotechnology, Pochon CHA University*

### ABSTRACT

Hematopoietic stem cells (HSC) are multipotent cells that reside in the bone marrow and replenish all adult hematopoietic lineages throughout the lifetime. In this study, we analyzed the expression of receptors of P2Y<sub>10</sub>, purinergic receptor families in murine hematopoietic stem cells, hematopoietic progenitor cells. In addition, the biological activity of P2Y<sub>10</sub> was investigated with B lymphocyte cell line, Ba/F3 in effect to cell growth and cell cycle. From the analysis of expression in hematopoietic stem cell and progenitor with RT-PCR, P2Y<sub>10</sub> was strongly expressed in murine hematopoietic stem cells (c-kit<sup>+</sup> Sca-1<sup>+</sup> Lin<sup>-</sup>) and progenitor cell population, such as c-kit<sup>+</sup> Sca-1<sup>+</sup> Lin<sup>-</sup>, c-kit<sup>+</sup> Sca-1<sup>-</sup> Lin<sup>-</sup> and c-kit<sup>-</sup> Sca-1<sup>-</sup> Lin<sup>-</sup>. To investigate the biological effects by P2Y<sub>10</sub>, retroviral vector from subcloned murine P2Y<sub>10</sub> cDNA was used for gene introduction into Ba/F3 cells, and stable transfectant cells were obtained by flow cytometry sorting. In cell proliferation assay, the proliferation ability of P2Y<sub>10</sub> receptor gene-transfected cells was strongly inhibited, and the cell cycle was arrested at G1 phase. These results suggest that the P2Y<sub>10</sub> may be involved in the biological activity in hematopoietic stem cells and immature B lymphocytes.

(Key words : Hematopoietic stem cells, P2Y<sub>10</sub>, Ba/F3, Cell proliferation, Cell cycle)

### INTRODUCTION

Stem cells hold great promise for regenerative medicine and cell-based therapies (Lagasse et al., 2001). Many somatic tissues, such as liver, intestine, skin and muscle are replenished from their respective stem cell compartments, but the best characterized stem cells are those responsible for hematopoiesis (Morrison et al., 1997; Ema et al., 2000). Hematopoietic stem cells (HSCs) are multipotent cells that reside in the bone marrow and give rise to all adult hematopoietic lineages throughout the lifetime of the animal and are self-renewal cells that regenerate HSC cells itself for long time (Ross et al., 1982; Anderson et al., 2001). HSC was used for transplantation of the treatment of congenital, malignant, and degenerative diseases so far (Blau et al., 2001).

Extracellular nucleotides, adenosin triphosphate (ATP) or uridine triphosphate (UTP) was made from cell lysis, exocytosis, or membrane transport proteins (Ryten et al., 2002; Ryu et al., 2003). The biological effects of nucleotides were reported as cell proliferation, differentiation, chemotaxis, cytokine secretion, generation of reactive oxygen or nitrogen species, as well as induction of cell death in various cell types (Sak et al., 2003; McCloskey et al., 1999; Honda et

al., 2001; Idzko et al., 2003; Idzko et al., 2003). The cell membrane protein against purines and pyrimidines for introduction into inside of cells was consisted of two main families, P1 receptor, and P2 receptors, recognizing primarily ATP, ADP, UTP, and UDP. From difference of molecular structure and signal transduction mechanism, P2 receptors were divided with two subfamilies of ligand gated ion channels and G protein-coupled receptors, P2X and P2Y receptors, representatively (Von et al., 2000; DuByak et al., 1993).

P2Y receptor families were consisted with typical G protein-coupled receptor with seven transmembrane domains. The transduction of signaling into intracellular by P2Y receptor was conducted by activation of phospholipase C and stimulation or inhibition of adenylyl cyclase by stimulation of ATP and UTP agonist. In P2Y subunits, there are three ADP-specific receptors (P2Y<sub>1</sub>, P2Y<sub>12</sub>, and P2Y<sub>13</sub>), one subtype of P2Y<sub>11</sub> for specific to ATP, as well as equipotent agonists of ATP and UTP against P2Y<sub>2</sub> (Ralevic et al., 1998; North et al., 2000).

P2X subfamilies were constitute with seven subunits clone so far and expressed on various mature hematopoietic cells. In special, the function of P2X<sub>7</sub> receptor in blood cells was shown that correlation with severity of disease in chronic lymphocytic leukemia (CLL) cells, suggesting that

<sup>†</sup> Corresponding author : Dong-Ku Kim, Cell and Gene Therapy Research Institute, Graduate School of Life Science and Biotechnology, Pochon CHA University, 605 Yeoksam 1-dong, Gangnam-gu, Seoul 135-907, Korea. Phone: +82-2-3468-3394, Fax: +82-2-3468-3264, E-mail: dokukim@hanmail.net

novel therapeutic target molecules of chronic leukemia. Among P2Y families, the P2Y<sub>2</sub> receptor is expressed in the myeloid lineage from myeloblast to mature neutrophils with involving the control of chemotaxis, superoxide anion production. Furthermore, P2Y<sub>2</sub> receptor is also active in eosinophils by ATP and UTP stimuli, with production of reactive oxygen metabolites and chemotaxis, as well as P2Y<sub>11</sub> was expressed in myeloid precursor and play a role in granulocytic differentiation using human leukemic cell lines, HL-60 and NB4, and also regulated the maturation of human monocyte-derived dendritic cells(DC) which has potent antigen presenting cells in immune system(Di et al., 2001; Flzoni et al., 1995; Suh et al., 2001; Ferrari et al., 2001).

Recently, the expression of P2 receptor families were investigated by purified hematopoietic stem cells from human using CD34 sorted cells and tried to define the physiological function with treatment of ATP/UTP *in vitro* cell culture, showing the several P2X subfamilies (P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub>, P2X<sub>7</sub>) were expressed, and also P2Y<sub>1</sub> and P2Y<sub>2</sub> subtypes were expressed, but not P2Y<sub>4</sub>, P2Y<sub>6</sub>, P2Y<sub>11</sub> subtypes in CD34+ human hematopoietic stem cell lineage, by RT-PCR analysis. In addition of extracellular nucleotides into human hematopoietic stem cell *in vitro*, the several cytokines was induced and enhanced the biological effects as stimulatory activator in human CD34+ hematopoietic stem cells (Roberto et al., 2004).

P2Y<sub>10</sub> was identified as PU.1/Spi-B target genes by subtractive hybridization in B cells, restricted to lymphoid cells, having the promoter region binding with PU.1/SP-B functionally required for efficient transcription in B cells. However, the expression of P2Y<sub>10</sub> in hematopoietic stem cells was not known, even its biological character too. Furthermore, in process of maturation and differentiation of hematopoietic stem cells, little was known the biological activity by extracellular nucleotides.

In this report, we analyzed the expression of P2Y<sub>10</sub> receptor in hematopoietic stem cells and hematopoietic progenitor by RT-PCR analysis, as well as the physiological function was investigated with overexpression of P2Y<sub>10</sub> receptor using retroviral gene introduction in B lymphocyte cell line, Ba/F3 using cell proliferation assay and cell cycle analyses.

## METHODS AND MATERIALS

### Cloning of Murine P2Y<sub>10</sub> cDNA

Total RNA was isolated from bone marrow cells of C57BL/6 mice using TRIzol reagent (GIBCO BRL, Rockville, MD, USA). cDNA synthesis from total RNA of bone marrow was conducted by following the protocol of superscript pre-amplification system. Briefly, after incubation of 5ug total RNA with 0.5ug Oligo(dT)12-18 primer at 70°C for

10min, the reaction was carried out in 5X first strand buffer, 10mM DTT and 0.5mM dNTP containing a final volume of 20ul mixture. Mixed contents of the tube were incubated at 42°C for 2min. And then, Superscript III(GIBCO) was added and incubated for 50min at 42°C and 15min at 70°C to synthesize cDNA. The primers for subcloning of murine P2Y<sub>10</sub> cDNA with PCR reaction was used as sense 5' GGA TCC ATG GCC TGG GAG CCC ACA TAC, anti-sense 5' GAA TTC TCA CTG CCC TGG GAG CTC AGC. And the PCR products eluded and cloning into pGEM-T subcloning vector, cloned pGEM-T easy-P2Y<sub>10</sub> verified by sequencing.

### RT-PCR Analyses

For RT-PCR, total RNA was isolated from total 10<sup>4</sup> ~10<sup>5</sup> cells of c-kit+ Sca-1+Lin-, c-kit- Sca-1+Lin-, c-kit+ Sca-1-Lin-, c-kit- Sca-1-Lin- hematopoietic stem cell and progenitor cells from bone marrow by FACSvantage and used the cell-to-cDNA kit(Ambion) with following the protocol of the manufacturer for confirmation of gene expression. For RT-PCR, 2μl cDNA was amplified using murine P2Y<sub>10</sub> sense primer was 5' GGA TCC ATG GGC AGC AAC AGT ACC AGC A and anti-sense primer was 5' GGA TTC CAA GGT TCA GTT AAA GAA ATT ATT T in a total volume of 50μl using pfu polymerase (Stratagen, USA). As negative control, RNA minus reverse transcriptase (RT)-prepared cDNA was used in PCR reactions. The aliquots of PCR reaction were used for confirmation of expression with agarose gels. The condition of RT-PCR were following; 35 cycles of 45s denaturation (94°C), 30s annealing (55°C), and 60s extension(72°C). The amount of cDNA for RT-PCR each sample was normalized with β-actin primer, sense : 5' AGG CTG TGC TGT CCC TGT ATG C-3', antisense: 5'-ACC CAA GAA GGA AGG CTG GAA A-3'. Condition of PCR for β-actin is 35 cycles of 30s at 94°C, 30s of annealing(50°C), 30s extension(72°C).

### Cell Culture

To investigate the physiologic function of P2Y<sub>10</sub>, pre-B cell lines, Ba/F3, were cultured in DMEM (GIBCO BRL) supplemented with 10% FBS (GIBCO BRL), penicillin and streptomycin, and 5ng/ml rmIL-3 (R&D system, USA). Retroviral package cell line, Plat-E were grown in DMEM supplemented with 10% FBS, penicillin and streptomycin, 10ug/ml blasticidin S (GIBCO BRL) and 2ug/ml puromycin (Sigma)

### Flow Cytometry Analysis and Cell Sorting

Flow cytometer, FACS VantageSE, were used for cell analysis and sorting. Antibody conjugates and matched isotype controls obtained from PharMingen or eBioscience; lineage markers CD3, CD4, CD8, Gr-1, Ter-119, Nk1.1, CD11b, CD45R and B220 (all APC); CD117 (c-Kit, FITC), Ly6/E (Sca-1, PE). For isolation of CD4+, CD8+ and B220+ lymphocytes from lymph node, cells was stained with CD4-FITC, CD8-PE, B220-APC conjugated antibodies. All

antibodies used were obtained from BD Biosciences or eBioscience. Cells for analysis and sorting from lymph node and bone marrow were incubated with indicated antibodies at 4 °C for 30min in staining media (SM), PBS containing with 3% FCS and 0.05% sodium azide. After antibody reaction, cells were washed 2 times with staining media for removing non-binding antibodies from reaction mixture. Finally, antibodies stained cells were applied the FACS vantage sorter for purification of hematopoietic stem cell and progenitor cells, and 5 µg/ml of propidium iodide (PI) solution was added to remove death cells in process of analysis and sorting. For analysis of data, 10,000 to 30,000 cells were stocked for further FACS analysis. All data from FACS for analyses and sorting was analyzed using CellQuest (BD) program.

To confirm the expression of P2Y<sub>10</sub> in retroviral infected Ba/F3 cell line, antibodies against FLAG obtained from Sigma were used for cell surface staining at dilution of 1:2,000 and then conducted FACS analysis, whether expressed or not on cell membrane at 48 hour after infection.

#### Construction of Retroviral Vectors and Gene Introduction

For all retroviral transduction experiments, the murine stem cell virus retroviral expression vector, pGCDN-IRESGFP used, which contained an internal ribosomal entry site (IRES) in front of the enhanced GFP (EGFP). The pGEM-T easy P2Y<sub>10</sub> was subcloned from pCDNA 3.1-Hygro-FLAG (Invitrogen, USA) into the EcoRI-XhoI site. Subsequently, the PmeI-XhoI fragment from pCDNA 3.1-Hygro-FLAG-mP2Y<sub>10</sub> was subcloned into the SnaBI-XhoI site from the pGCDN-IRESGFP. All constructs were verified by sequencing. Stable high titer retroviral producer cell lines were generated by transiently transfected Plat-E cells using 3 µg DNA and the Exgen500 (Fermentas, St. Leon-Rot, Germany). High titer retroviral producer Plat-E cell lines were selected by stringent GFP<sup>+</sup> cell sorting. Retroviral supernatants were harvested from stable Plat-E cell line and then concentrated by centrifugation with 15,000rpm, for over night at room temperature. After suspended at RPMI culture media, retrovirus was introduced the Ba/F3 cell lines for 2 days, and then conducted the sorting of GFP<sup>+</sup> cells with FACSvantage to obtain the stable cell line and maintain for cell proliferation experiment and cell cycle analysis.

#### Cell Proliferation Assay

Cell proliferation was performed using a cell proliferation kit I (Roche) according to the manufacturer's instructions. The cells were plated in 96 well tissue culture plates at a density of 5 × 10<sup>4</sup> cells/well and cultured. At the culture period from day 1 to 4, 10 µl MTT labeling reagent added. Incubate the plate for 4h in a 37.5% CO<sub>2</sub>. After allowing the plate to stand overnight, absorbance in immunoreader was measured at 545nm.

#### Cell Cycle Analysis

Cells were maintained at the presence of rmIL-3 (5 µg/ml) with normal and P2Y<sub>10</sub> transduced Ba/F3 cell lines. For cell cycle analysis, cells were harvested at 2 days after culture, and then fixed with ethanol and conducted RNase digestion. Propidium iodide (5 µg/ml, Sigma) was stained for 30min and then analyzed cell cycle with using BD Modifit LT software.

## RESULTS

#### Characterization of Murine P2Y<sub>10</sub> Receptor

To obtain the full length of cDNA of murine P2Y<sub>10</sub> receptor, we performed RT-PCR with total bone marrow cells from mouse. To characterize the genetic properties of mouse P2Y<sub>10</sub> gene, the complete amino acid sequences of human, mouse and rat protein were compared the properties of similarities at level of amino acid. Deduced amino acid sequences were analyzed with the multiple alignment programs, t-coffee. The amino acid of P2Y<sub>10</sub> receptor from human, mouse and rat was consisted of 339, 328 and 328 amino acid (Fig. 1). The amino acid similarities were analyzed by cluster W, multiple alignment programs. The homology of amino acid in P2Y<sub>10</sub> receptor between human and mouse has shown almost 85%, and 92% of homology between mouse and rat. P2Y<sub>10</sub> receptor was composed with seven transmembrane domains.

#### Expression of Murine P2Y<sub>10</sub> Receptor in Hematopoietic Stem Cells

At the previous report, expression of P2Y<sub>10</sub> in various murine tissues was investigated with Northern blot analysis. From this analysis, P2Y<sub>10</sub> mRNA was mainly expressed in spleen and thymus organs and very low levels of expression detected in bone marrow, but not other organs, lung, liver, brain and kidney. In addition, when analysis with murine cell line, P2Y<sub>10</sub> was expressed exclusively in immature and mature T cells, immature and mature B cells. However, it was not expressed in macrophage, erythrocyte, or fibroblast cells line. Interestingly, the analysis of RT-PCR of murine P2Y<sub>10</sub> specific primer with murine organs, we observed the high expression in bone marrow, brain, kidney and also relative expression in spleen and liver (data not shown). For further detail analysis of its expression in hematopoietic cell lineage, hematopoietic stem cells and progenitor cells from bone marrow was sorted by staining with c-kit, Sca-I antibodies and lineage antibodies (CD3, CD11b, B220, GP-A) using FACSvantage. From analysis of RT-PCR with adult bone marrow, the P2Y<sub>10</sub> was expressed very strongly in hematopoietic stem cells (c-kit<sup>+</sup> sca-1<sup>+</sup> Lin<sup>-</sup>) and progenitor cell population, c-kit<sup>+</sup> sca-1<sup>-</sup> Lin<sup>-</sup>, c-kit<sup>-</sup> sca-1<sup>+</sup> Lin<sup>-</sup> and c-kit<sup>-</sup> sca-1<sup>-</sup> Lin<sup>-</sup>.






Fig. 4. P2Y<sub>10</sub> inhibited Ba/F3 cell proliferation. P2Y<sub>10</sub> transfected Ba/F3 were cultured for 4 days and conducted cell proliferation activity with MTT assay (◆: Ba/F3+IL-3, ■: Ba/F3-P2Y<sub>10</sub>+IL3 ▲: Ba/F3, ●: Ba/F3-P2Y<sub>10</sub>).

of IL-3 was maintained and sustained the proliferation and growth of Ba/F3 cell line *in vitro*. To identify expression of P2Y<sub>10</sub> on surface of cell, anti-Flag antibody was used for analysis of flow cytometry with Ba/F3 cell line, and then sorted for culture. As shown, cells transfected with P2Y<sub>10</sub> receptor were detected up 70% positive on surface of cells (Fig. 3B), which was obtained same result from morphological analysis with single cells (data not shown).

#### P2Y<sub>10</sub> Overexpression Inhibits Proliferation for Ba/F3 Cells

To define the biological function of P2Y<sub>10</sub> receptor in B cell line, P2Y<sub>10</sub> over-expressed Ba/F3 cells were sorted to obtain complete P2Y<sub>10</sub> introduced cells by flow cytometry and cultured in the absence or presence of rhIL-3 at indicated time. As shown in Fig. 4, control Ba/F3 cells was shown a normal proliferation with stimulation of rhIL-3. However, stable over-expression of P2Y<sub>10</sub> receptor on cell surface made the growth retardation in spite of the presence of rhIL-3. The difference of ability of cell growth between P2Y<sub>10</sub> expressed cells and normal cells, was shown a very high level at day 3 from culture start in P2Y<sub>10</sub> over-expressing cell line. This result implies that P2Y<sub>10</sub> receptor might be possessed the anti-proliferation activity in pro-B cells.

#### P2Y<sub>10</sub> Gene Regulates Cell Cycle in Ba/F3 Cells

To survey the reason of growth retardation by P2Y<sub>10</sub> overexpression on Ba/F3 cell, we tried cell cycle analysis whether P2Y<sub>10</sub> involved the cell cycle arrest; result in a very low cell proliferation activity. We analyzed the cell cycle analyses with P2Y<sub>10</sub> over-expressing cells and control cells using flow cytometry by PI staining. As shown in Fig. 5, P2Y<sub>10</sub> over-expressing cells were revealed a relatively high cell cycle arrest at the stage of G0/G1 (45.6%) and a low level at G2 phase (0.02%) stage, as well as S phase (54.4%),




Fig. 5. Cell cycle analysis of P2Y<sub>10</sub> transfected Ba/F3 cell line. (A) control cells (B) P2Y<sub>10</sub> gene transfected cells.

compared with control cells, G0/G1 of 37.8%, G2 phase of 2.3% and S phase of 59.9%, at day 2 of culture. These data implicates that P2Y<sub>10</sub> receptor might regulate the cell proliferation with cell cycle adjustment in pro-B cell line, Ba/F3.

## DISCUSSION

Extracellular effects of nucleotides were initially recognized in smooth muscle contraction, neurotransmission, regulation of cardiac function, and platelet aggregation. In addition, blood cells have emerged as one of their most interesting targets for investigating the biological activity of nucleotides through this transmembrane receptor to introduce the intracellular signals, such as cell activation, proliferation and apoptosis (Di et al., 2001; Falzoni et al., 1995). The receptors against extracellular nucleotides, ATP and UTP were divided into two subfamilies, ligand-gated ion channels (P2X) and G protein-coupled (P2Y) receptor. P2Y receptors are seven membrane spanning proteins and signal transduction occurs via the classical pathways triggered by receptor as the pathway of activation of phospholipase C and stimulation or inhibition of adenylate cyclase. ATP induces the activation of all of P2Y receptors, but P2Y<sub>4</sub> and P2Y<sub>6</sub> receptor is more susceptible to UTP than ATP potent.

Functional P2Rs for extracellular nucleotides have been found in many mature blood cells and their activation has been associated with stimulation of responses as their activation has been associated with stimulation of responses as different as chemotaxis, cytokine secretion, proliferation, and cell death. More recently P2X<sub>7</sub>R has also been identified on B leukemic cells and its expression was found to correlate with an aggressive course of the disease. Although the interest for nucleotides as potential regulators of blood cell functions has steadily increased, so far no studies have addressed the issue of whether P2Rs are expressed on hematopoietic stem cells and whether their ligation induces the functional activation of hematopoietic stem cells.

In this study, we investigated the expression characteristic in hematopoietic stem cells and also hematopoietic precursor cells from mouse bone marrow. Cells isolated with flow cytometry using hematopoietic stem cells specific maker, c-kit and Sca-1 in lineage negative cell population in bone marrow, was used for determination of expression of P2Y<sub>10</sub> receptor gene. From RT-PCR result, P2Y<sub>10</sub> receptor gene was highly expressed in hematopoietic stem cells and also progenitor cells. This result imply that P2Y<sub>10</sub> might be involved the biological function in early hematopoietic development from stem cells to mature hematopoietic cells. For the analyses the biological activity of P2Y<sub>10</sub> receptor gene, Ba/F3 cells, B lymphocyte progenitor cell line, was used by introduction of P2Y<sub>10</sub> gene with retroviral gene delivery to induce the overexpression. P2Y<sub>10</sub> over-expressed cells was shown the dramatically growth retardation in presence with IL-3 compared with that of control cells by detection with cell proliferation assay. Together, P2Y<sub>10</sub> gene transfected cells withdraw of cell survival factor, IL-3 were shown severely deceased their survival rate with non-transfected cells. This result mentioned that P2Y<sub>10</sub> gene regulated cell growth and survival in Ba/F3 cell lines directly. To confirm the mechanism how to regulate the cell growth, cell cycle analyses was conducted in P2Y<sub>10</sub> gene transfected cells and P2Y<sub>10</sub> non-transfected cells. Interestingly, P2Y<sub>10</sub> overexpression cells were shown high cell cycle arrest at G0 phase and G2 phase cells was eventually shown low cells population, but S phase cells was not shown severe difference compared with control cells.

These data implicates that P2Y<sub>10</sub> receptor may be a very strong candidate to modify and regulate the cell proliferation and large expansion of hematopoietic stem cells and also to cure of B lymphoid malignance disease for clinical application by gene therapy or expression regulation.

## REFERENCES

1. Anderson DJ, Gage FH, Weissman JM (2001): Can stem cells cross lineage boundaries? *Nat Med* 7:393-395.
2. Blau HM, Brazelton TR, Weimann JM (2001): The evolving concept of a stem cell: entity of function? *Cell* 105: 829-841.
3. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR (2001): Nucleotide receptors: an emerging family of regulatory molecules in blood cells. *Blood* 97:587-600.
4. Ema H, Nakauchi H (2000): Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. *Blood* 95:2284-2288.
5. Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S, Di virgilio F (1995): The purinergic P2Z receptor of human macrophage cells: Characterization and possible physiological role. *J Clin Invest* 95: 1207-1216.
6. DUBYAK GR, El-Moatassim C (1993): Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. *Am J Physiol* 265:577-606.
7. Ferrari D, La Sala A, Chiozzi, Morelli A, Falzoni S, Girolomoni G, Idzko M, Dichmann S, Norgauer J, Di Virgilio F (2001): The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. *FASEB J* 14:2466-2476.
8. Honda S, Sasaki Y, Ohsawa K, Imai Y, Nakamura Y, Inoue K, Kohsaka S (2001): Extracellular ATP or ADP induce chemotaxis of cultured microglia through G1/0-coupled P2Y receptors. *J Neurosci* 21:1975-1982.
9. Hogquist KA, Unanue ER, Chapline DD (1991): Release of IL-1 from mononuclear phagocytes. *J Immunol* 147: 2181-2186.
10. Idzko M, Dichmann S, Ferrari D, Di Virgilio F, la Sala A, Girolomoni G, Panter E, Norgauer J (2003): Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2Y receptors. *Blood* 100: 925-932.
11. Idzko M, Panther E, Bremer HC, Schriecher S, Luttmann W, Virchow CJ Jr, Di Virgilio F, Herouy Y, Norgauer J, Ferrari D (2003): Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. *Br J Pharmacol* 138:1244-1250.
12. Lagasse E, Shizuru JA, Uchida N, Tsukamoto A, Weissman IL (2001): Toward regenerative medicine. *Immunity* 14:425-436.
13. Lemoli RM, Ferrari D, Fogli M, Rossi L, Pizzirani, Forchap S, Chiozzi P, Vaselli D, Bertolini F, Foutz T, Aluigi M, Baccarani M, Virgilio FD (2004): Extracellular nucleotides are potent stimulators of human hematopoietic stem cells *in vitro* and *in vivo*. *Blood* 15: 1662-1670.
14. McCloskey MA, Fan Y, Luther S (1999): Chemotaxis of rat mast cells toward adenine nucleotides. *J Immunol* 163:970-977.
15. Morrison SJ, Shah NM, Anderson DJ (1997): Regulatory mechanism in stem cell biology. *Cell* 88: 287-298.
16. Moore KA, Ema H, Lemischka IR (1997): *In vitro* maintenance of highly purified, transplantable hematopoietic stem cells. *Blood* 89:4337-4347.
17. North A, Surprenant AM (2000): Pharmacology of cloned P2X receptors. *Annu Rev Pharmacol Toxicol* 40:563-580.
18. Ross EA, Anderson N, Micklem HS (1982): Serial depletion and regeneration of the murine hematopoietic system. Implications for hematopoietic organization and the study of cellular aging. *J Exp Med* 155:432-444.
19. Ryten M, Dunn PM, Neary JT, Burnstock G (2002): ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X<sub>5</sub> receptor on satellite cells. *J Cell Biol* 158:345-355.
20. Ryu JK, Choi HB, Hatori K, Heisel RL, Pelech SL, McLarnon JG, Kim SU (2003): Adenosine triphosphate induces proliferation of human neural stem cells: role of

- calcium and P70 ribosomal protein S6 kinase. *J Neurosci Res* 72:352-362.
21. Ralevic V, Burnstock G (1998): Receptors for purines and pyrimidines. *Pharmacol Rev* 50:413-492.
  22. Sak K, Boeynaems JM, Everaus H (2003): Involvement of P2Y receptors in the differentiation of hematopoietic cells. *J leukoc Biol* 73:442-447.
  23. Suh BC, kim JS, Namgung U, Ha H, Kim KT (2001): P2X<sub>7</sub> nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils. *J Immunol* 166:6754-6763.
  24. Von Kugelgen I, Wetter A (2000): Molecular pharmacology of P2Y-receptors. *Naunyn Schmiedebergs Arch Pharmacol* 62:310-323.
- (Received: 19 May 2005 / Accepted: 13 June 2005)